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Abstract
Pattern-recognition receptors (PRRs) promote host defenses against HCV infection by
binding to their corresponding adapter molecules leading to the initiation of innate immune
responses including cell death. We investigated the expression of PRR genes, biomarkers
of liver cell-death, and T cell and NK cell activation/inhibition-related genes in liver and
serum obtained from three experimentally infected chimpanzees with acute HCV infection,
and analyzed the correlation between gene expression levels and clinical profiles. Our
results showed that expression of hepatic RIG-I, TLR3, TLR7, 2OAS1, and CXCL10
mRNAs was upregulated as early as 7 days post-inoculation and peaked 12 to 83 days
post-inoculation. All of the three HCV infected chimpanzees exhibited significant elevations
of serum alanine aminotransferase (ALT) activity between 70 and 95 days after inoculation.
Elevated levels of serum cytokeratin 18 (CK-18) and caspases 3 and 7 activity coincided
closely with the rise of ALT activity, and were preceded by significant increases in levels of
caspase 3 and caspase 7 mRNAs in the liver. Particularly we found that significant positive
auto-correlations were observed between RIG-I, TLR3, CXCL10, 2OAS1, and PD-L1
mRNA and ALT activity at 3 to 12 days before the peak of ALT activity. However, we
observed substantial negative auto-correlations between T cell and NK cell activation/inhi-
bition-related genes and ALT activity at 5 to 32 days after the peak of ALT activity. Our
results indicated cell death signaling is preceded by early induction of RIG-I, TLR3, 2OAS1,
and CXCL10 mRNAs which leads to elevation of ALT activity and this signaling pathway
occurs before the activation of NK and T cells during acute HCV infection. Our study sug-
gests that PRRs and type I IFN response may play a critical role in development of liver cell
injury related to viral clearance during acute HCV infection.
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Introduction
HCV infection is the most common blood-borne infection in the US, with approximately 3
million persons living with the infection [1]. Percutaneous exposure to contaminated blood is
the most frequent mode of HCV transmission with injecting drug use (IDU) being the pre-
dominant risk factor for infection. Surveillance data show that from 2006–2012, there was a
nationwide increase in reported cases of acute HCV infection, with the largest increases occur-
ring east of the Mississippi River, particularly in the Appalachian states [2]. Nationwide, nearly
30,000 acute hepatitis C infections are estimated to have occurred in 2013. Demographic and
behavioral data show further that the majority of cases were among young persons (aged30
years) from nonurban areas with IDU as the principal risk factor [3].
Acute hepatitis C is defined by the presence of any sign or symptom of acute viral hepatitis
plus either jaundice or elevated serum alanine aminotransferase (ALT) activity, with sero-
logic evidence of anti-HCV antibody or HCV RNA within 6 months of exposure. In 2012,
the case definition for acute HCV infection was expanded to include cases with negative
HCV antibody in blood followed by positive antibody within 6 months [3]. However, most
people with acute HCV infection at time of diagnostic testing are already positive for anti-
HCV antibody.
Biomarkers of host response to HCV during the early phase of infection may be used as an
adjunct to diagnose acute hepatitis C more definitively and to provide a sharper case definition
for acute hepatitis C [4]. Host responses include those generated by innate and adaptive immu-
nologic mechanisms and those relating to cell death signaling. Studying the chimpanzee model
of HCV infection allows host responses to be analyzed closely, particularly during the early
stage of infection.
In experimentally infected chimpanzees, HCV RNA can be detectable in blood in 1 to 2
weeks after inoculation and is maintained for an additional 8 to 18 weeks [5–9]. SerumALT
activity peaks between 6 and 10 weeks, when levels of HCV RNA begin to decline. ALT activity
is an indicator of liver injury induced hepatocytic death. Two main mechanisms of cell death
have been described; disordered necrosis and programmed apoptosis. Studies have shown that
these two processes are part of the same death spectrum [10, 11]. Apoptosis is induced intrinsi-
cally by mitochondrial death and extrinsically following triggering of the cell death pathway by
receptors such as the tumor necrosis factor (TNF)α, Fas ligand (FASL), and TNF-related apo-
ptosis-inducing ligand (TRAIL) [11]. Cysteine-aspartate proteases called caspases, are activated
at the end of both pathways, and may be classified into two major groups: initiator caspases
(such as caspases 2, 8, 9, and 10), which confer regulatory function; and effector caspases (such
as caspases 3, 6, and 7), which execute apoptotic cell death [12].
HCV activates pattern-recognition receptors (PRRs) including Toll-like receptors (TLRs)
and retinoic acid-inducible gene 1 (RIG-I) very early after infection [13]. PRRs initiate mecha-
nisms to eliminate viral infection as a part of the host innate immune response [14]. Strong
host immune responses are induced days after HCV infection in chimpanzees in which many
of the immune response genes are found to be IFN-stimulated genes (ISG) [5, 7–9]. Activation
of ISG in the early phase of acute HCV infection are initiated by detecting viral pathogen asso-
ciated molecular patterns (PAMPs) through PRRs. PRR-induced responses are involved in the
production of pro-inflammatory cytokines, type I and type III interferons (IFNs), which
together act to limit viral replication by initiating cell death [15–21]. Exact mechanisms of
interaction between IFN induction and apoptosis are unclear. However, it is known that TLR
proteins recognize RNA as ligand and inducting type I and type III IFN responses [22, 23], for
example, RIG-I, a cytosolic RNA helicase, that can recognize both double-stranded and single-
stranded RNA can then induce a downstream signaling cascade that finally leads to apoptosis
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[24]. In addition, HCV-specific T cells and NK cells also have been shown to be associated with
virus clearance and hepatic injury from apoptosis [25, 26].
We report here the kinetics of hepatic gene expression of markers of innate and adaptive
immunity and of cell death signaling and the appearance of biomarkers in peripheral blood
generated from such expression in HCV-infected chimpanzees during the acute phase. We
show the markers of innate immunity and cell death signaling both in the liver and serum pre-
cede or coincide with rise of serum ALT activity, whereas the markers of adaptive immunity in
the liver and the blood tend to occur after the peak of serum ALT activity.
Materials and Methods
Chimpanzees
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of LaboratoryAnimals of the Centers for DiseaseControl and Prevention. The
protocol was approved by the Institutional Animal Care and Use Committee of the Centers for
DiseaseControl and Prevention (Protocol Number: 1363KRACHIC). The animals were anesthe-
tized by the Animal Resource Branch personnel with tiletamine (telazole) for liver biopsy in the
dose of 5mg/kg through intermuscular (IM), ketamine HCL was used to sedate for blood collec-
tion with 10 mg/kg dose through IM, and all efforts were made to minimize suffering. The diet
consisted of a mixture of a high-protein chow (Lab Diet High-Protein Monkey Diet 5045, PMI
Nutrition International, Saint Louis,MO), high-fiber chow (Fiber-Plus Monkey Diet 5049, PMI
Nutrition International), various fruits and vegetables, and treats (Bio-serv, Frenchtown, NJ).
Animals were singly and pair housed in accordance with federal laws, regulations, and the Guide
for the Care and Use of LaboratoryAnimals. Prior to inoculationwith hepatitis C and at the con-
clusion of the study, animals were pair housed. After inoculationwith hepatitis C, animals were
housed individually (the approximate floor area was over 25.1 sq ft) to prevent viral transmission
but were allowed visual and auditory contact with one another. Environmental enrichment con-
sisted of social (e.g. pair housing and human interaction), structural (e.g. swings, perches, tun-
nels), manipulanda (e.g. various toys rotated on a weekly or biweekly basis), sensory (e.g. visual,
tactile, and olfactive such as television,music, videos, etc.), various novel food items, and various
foraging opportunities. Analgesic used for pain relieve was injectable and oral meloxicam (Meta-
cam, Boehringer Ingelheim, St Joseph, MO) administered intramuscularly immediately after the
liver biopsy and orally on subsequent days of treatment at a dosage of 0.3mg/kg. The study was
done betweenAug, 2005 and March, 2006. Three chimpanzees (CH1541, CH256, and CH6413)
were inoculated intravenously with HCV genotype 1a. The inocula varied from 103 to 103.5 chim-
panzee infectious doses (CID) [27–29]. Serum samples were tested at baseline and weekly after
inoculation for HCV RNA using the CobasAmplicor system according to manufacturer’s recom-
mendation (detection limit: 600 IU/ml) (Roche Molecular Systems, Pleasanton, CA) and further
quantified using the Amplicor Monitor system (Roche Molecular Systems). Anti-HCV IgG was
measured using the ORTHO 3.0 ELISA test system (Ortho-ClinicalDiagnostics, Raritan, NJ).
ALT activity was measured using the assay manufactured by Drew Scientific (Dallas, TX) and the
cut-off value for each chimpanzee was set as 3 standard deviations above the mean of 9 or 10 pre-
inoculation serumvalues.
Gene expression of apoptosis, innate, and adaptive immune response
markers in liver and PBMC specimens
Weekly liver needle biopsies were obtained at baseline and after HCV inoculation. Total RNA
was extracted from liver biopsy samples and PBMCs using the TRIzol Plus RNA purification
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kit according to manufacturer’s recommendation (Ambion, Austin, TX). cDNA was pre-
pared using 100 ng of total RNA by a high-capacity reverse transcription kit (Applied Biosys-
tems, Foster City, CA) and used as template for real-time PCR performed using the SYBR
green PCR JumpStart Master Mix (Sigma, St. Louis, MO) for caspase-3, caspase-7, caspase-8,
caspase-9, caspase-10, and APAF-1 transcripts. Transcripts of 2OAS-1, RIG-1, TLR3, TLR7,
TNFα, CXCL10, perforin, CXCR3, CCR1, CCR7, NKG2D, KIR2D, CD8β IFNγ, CD86, PD-
1, PD-L1, CTLA-4, and Tim-3 in liver, and PBMCs were analyzed by Taqman real-time PCR
using Applied Biosystems 7900HT Fast Real-time PCR system (Life Technologies, Grand
Island, NY). Information about sequences of primers and probes is described in Supporting
materials (S1 Materials and Methods). Greater than two-fold changes (2-ΔΔCT) in altered
gene expression were considered to be significant. Each gene’s mRNA level was normalized
to an endogenous reference gene and expressed as an increase over baseline liver tissue
levels.
Cytokeratin-18 and caspase 3/7 activity in serum
The apoptosis-mediated neoepitope (M30 antigen) located in the C-terminal domain of cyto-
keratin-18 (CK-18) (amino acid 387–396) was measured by the M30-Apoptosense ELISA
assay (Peviva AB, Bromma, Sweden). Caspase 3 and 7 activities in serumwere measured by
Caspase-Glo (Promega, Madison, WI). For both assays, cut-off values were calculated from 10
baseline specimens from each chimpanzee and set as the mean plus 1.6 times the standard
deviation. All assays were performed in duplicate.
Chemokines, and soluble PD-1 in serum/plasma specimens
Serum levels of CXCL10 were measured using ChemokineArray ELISA kit (RayBiotech, Nor-
cross, GA). Soluble PD-1 (sPD-1) was measured in serum or plasma using an in-house
enzyme-linked immunosorbent assay (ELISA), the details of which are included in the Sup-
porting Information. Cut-off values for sPD-1 were calculated for each chimpanzee from 10
serum samples obtained before HCV inoculation (CH6413: 0.17 ng/ml, CH256: 0.22 ng/ml,
and CH1541: 0.12 ng/ml). Background levels of sPD-1, determined from 24 plasma samples
obtained from historical control specimens of 3 naïve chimpanzees, were found not to exceed
0.1 ng/ml.
Statistical analysis
To investigate the relationship between hepatic mRNA expression, serumprotein levels, serum
HCV RNA titer, and ALT activity during acute HCV infection, Pearson and lag correlation
tests were performed.Mean values of observeddata from all three animals were used due to
the consistency and similarity of HCV RNA concentration and ALT profiles in each animal.
The Pearson correlation test was performed using SPSS software version 21 (IBM Inc. Armonk,
NY) and the Comprehensive R Archive Network (CRAN), Bioconductor (R software version
3.2.2) [30] was used for the lag correlation tests. Lagged temporal correlations were calculated
between each biomarker and ALT activity after shifting expression data to align with the peak
of ALT activity [31]. Linear interpolation was applied when necessary because of the occur-
rence of missing or uneven sampling time points. The alignment was done such that the time
corresponding to the highest values of the two observed curves overlap exactly. All statistical
tests were two-tailed and were considered significant at p 0.05. Smooth trajectory analysis
were performed using Prism 6 (GraphPad).
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Results
HCV RNA and ALT activity during acute HCV infection
Three chimpanzees were infected with HCV genotype 1a and exhibited the typical pattern of
HCV infection.HCV viremia was detected on day 4 in CH1541 and day 7 in CH256 and
CH6413; the animals seroconverted between days 70 to 88 (Fig 1A). The peak level of HCV
RNA was about 5.7 logs IU/ml. All three chimpanzees exhibited significant elevations of ALT
activity that peaked between 70 and 95 days after inoculation and returned to baseline levels
between days 88 to 153 after inoculation, at the time of serum HCV RNA decline. HCV RNA
detection in CH6413 and CH256 continued until the end of the 180 day observation period,
whereas CH1541 cleared HCV RNA by day 131.
HCV infection induces apoptosis in chimpanzees with acute HCV
infection
Caspase activation is a common feature of cell death through apoptosis. Caspase 3/7 activity
levels in serumof all three chimpanzees were elevated from 71 to 91 days after inoculation and
their peaks coincidedwith peak CK-18 levels (Fig 1B). Serum caspase 3/7 activity and CK-18
levels were closely correlated to ALT activity. Pearson correlation test confirmed that there is
statistically significant strong positive correlation between caspase 3/7 activity, CK-18, and
ALT activity (Table 1). In addition, in CH6413 and CH256, caspase 3 and 7 activities above-
baseline cutoff levels were detected from day 110 to 180. Increased levels of caspase-3 and cas-
pase-7 mRNAs in the liver were detected in all three animals, in which elevated mRNA expres-
sion was detected, from day 32 in CH1541, day 40 in CH256, and day 47 in CH6413. These
levels peaked approximately 20 days before the highest levels of elevated caspase 3/7 activity in
the corresponding serum samples (Fig 1B and 1C).
High levels of initiator caspase-8, -9, -10, and adaptor molecule, APAF-1 mRNAs were also
analyzed in the liver. In CH6413, expression of caspase 8, 9, 10, and APAF-1 mRNA was ele-
vated from days 47, 88, 75, and 32, respectively (Fig 1D). In CH256, high levels of mRNA
expression of caspase 8, 9, and APAF-1 were detected from days 40 to 75 and elevation of cas-
pase 10 mRNA expression was detected at day 75. In CH1541, expression of caspase 8, 9, and
10 mRNAs was elevated from day 32 and APAF-1 mRNA expression was highly elevated from
day 12 (7.2-fold change). Hepatic TNFαmRNA expression was elevated from day 82 to 180 in
CH6413, on days 95, 124, and from day 152 to 180 in CH256 (Fig 1E). Hepatic perforin
mRNA expression was elevated on day 4 and from day 12 to 180 and its peak level was detected
on day 125 in CH6413. In CH256, perforin mRNA expression was elevated on days 124 and
152. However, elevated expression of TNFα and perforin mRNAs was not detected in CH1541.
Expression of type I interferon and pattern recognition receptor gene
(PRR) expression in the liver
Intrahepatic expression of 20 50 oligoadenylate synthetase-1 (2OAS-1), type I interferon gene,
and RIG-I, TLR3, and TLR7 as PRRs was analyzed. Elevation of 2OAS-1 mRNA expression
was observedby day 12, coinciding with the appearance of serum HCV RNA, and peaked
before serum ALT began to rise in all chimpanzees (Fig 1F). Increased levels of 2OAS-1 mRNA
expression were maintained in CH6413 and CH256, but its expression had declined to baseline
levels towards the end of acute-phase infection in CH1541.
In CH6413, hepatic expression of RIG-I and TLR3 mRNAs peaked on day 12 and remained
elevated until day 32 or 53, and up-regulated again from day 103 to 180; TLR7 mRNA expres-
sion was elevated only on day 12 (Fig 1F). In CH256, hepatic expression of RIG-I mRNA and
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Fig 1. Apoptosis and expression of 2OAS-1, RIG-1, TLR3, and TLR7 mRNAs in livers of HCV-infected chimpanzees. (A),
Course of infection in chimpanzees during acute HCV infection. Serum HCV RNA levels are represented as a line graph; serum ALT
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TLR3 mRNAs was elevated from days 53 to 82 and 53 to 61, respectively, and high levels of
TLR7 mRNA expression were observed from days 152 to 180. In CH1541, RIG-I mRNA
expression was elevated from days 12 to 53, and on day 103; expression of TLR3 mRNA was
elevated on day 12, 47 to 53, and 103. High levels of TLR7 mRNA expression were detected on
day 46, and from day 82 to 103.
Hepatic expression of chemokines and natural killer cell activation
markers
Expression of chemokines, CXCR3, CCR1, CCR7, CXCL10, and NK cell activation marker,
NKG2D, and NK cell inhibition marker, KIR2DL2/3 receptor mRNAs was analyzed to deter-
mine whether these genes were involved in induction of liver injury. Hepatic expression of
CXCR3 and CCR1 mRNAs was elevated from day 61 to 124 in CH6413 and days 61 and 124 in
CH1541, but not in CH256 (Fig 2A). High expression of CCR7 mRNA was detected from days
61 to 152 in CH6413, on days 95 and 152 in CH256, and days 61 to 152 in CH1541. Hepatic
expression of CXCL10 mRNA was elevated from day 7 or 12 until the end of observation in
CH6413 and CH1541, respectively, and on days 19 to 82, 103 to 124, and 152 to 180 in CH256.
NKG2D mRNA was elevated between days 82 to 180 in CH6413, on day 152 in CH256, and
between days 103 and 152 in CH1541, but KIR2DL2/3 receptor mRNA expression was not ele-
vated in any of these chimps (Fig 2B).
Expression of T cell activation and inhibition markers
T activation and inhibition markers were analyzed to determine their relationship to the liver
injury. CD8βmRNA expression began to rise on days 82, 95 and 75 in CH6413, CH256, and
CH1541, respectively, and peaked betweendays 118 and 124. High levels of CD8βmRNA
expression were maintained until the end of acute phase of HCV infection in all chimpanzees.
(Fig 2C). The level of IFNγmRNA expression increased steadily as HCV viremia decreased and
its levels were elevated from day 82 for CH6413 and CH256 until the end of observation. For
CH256, IFNγ elevation was less marked than for the other two chimpanzees and levels declined
toward the end of the observationperiod.High levels of hepatic PD-1 and PD-L1 mRNA expres-
sions were found from days 61 to 180 and 40 to 180, respectively (Fig 2C). Up-regulation of PD-
1 mRNA expression continued until the end of the observationperiod in CH6413 and CH256,
while in CH1541, it had declined to baseline levels by day 124. The pattern of hepatic PD-L1
mRNA expression varied in all three chimpanzees. It fluctuated in CH1541 and CH6413 declin-
ing at the end of the acute infection. In CH256 it was still highly expressed at the end of acute
infection. In all three chimpanzees, hepatic PD-L1 mRNA expression preceded rise in hepatic
PD-1 mRNA expression. No significant changes in PD-1 and PD-L1 mRNA expression in
PBMCs were observed in any chimpanzee, although slight increases were noted only occasionally
in CH1541 (data not shown). CTLA4 mRNA expression was elevated from days 82 to 152 in
CH6413 and CH256, but not in CH1541. High levels of Tim-3 mRNA expression were detected
from days 47 to 180 in all three chimpanzees (Fig 2B). CD86 mRNA was elevated between days
53 and 124 in CH256 and CH1541, but that was not observed for CH6413 (Fig 2C).
levels are indicated as grey shading; seropositivity for anti-HCV IgG is represented by the bar. (B), Serum caspase 3/7 activity (red
line) and CK-18 levels (blue line) (C), Hepatic expression of caspase 3 (blue line) and 7 (red line) mRNAs (D), Levels of Caspase 8
(red line), Caspase 9 (green line), Caspase 10 (blue line), and APAF-1 (purple line) mRNAs in liver (E), Levels of TNFα (red line) and
perforin (blue lines) mRNAs (F), Levels of 2OAS-1 (blue line), RIG-I (red line), TLR3 (green line), and TLR7 (purple line) mRNAs in
liver. Each gene’s mRNA level was normalized to an endogenous reference gene and expressed as an increase over baseline liver
tissue levels.
doi:10.1371/journal.pone.0165533.g001
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Soluble PD-1 and CXCL10 levels in serum: possible serum markers for
detecting hepatic injury induced by acute HCV infection
Baseline levels of sPD-1 were analyzed using serum samples from 10 naïve chimpanzees and 8
samples from the 3 study chimpanzees obtained before experimental inoculation. Levels of
sPD-1 were measured at less than 0.2 ng/ml in all samples (data not shown). sPD-1 levels in
Table 1. Pearson correlation coefficients for association between HCV RNA, ALT activity and other markers in chimpanzees with acute HCV
infection.
HCV RNA ALT activity
Pearson correlation test r p value r p value
HCV RNA concentration 1 0.219 0.035
ALT activity 0.219 0.035 1
Gene expression in liver
RIG-I mRNA 0.475 0.012 -0.051 0.772
2OAS1 mRNA 0.709 < 0.01 0.207 0.184
TLR3 mRNA 0.198 0.322 -0.049 0.781
TLR7 mRNA -0.242 0.223 -0.059 0.735
PD-L1 mRNA 0.284 0.088 0.127 0.392
CXCL10 mRNA 0.496 0.005 -0.099 0.556
CXCR3 mRNA -0.328 0.077 -0.075 0.655
CCR1 mRNA -0.376 0.04 -0.132 0.428
CCR7 mRNA -0.077 0.687 -0.027 0.872
Caspase 3 mRNA 0.192 0.475 -0.068 0.795
Caspase 7 mRNA 0.072 0.791 -0.212 0.399
Caspase 8 mRNA 0.189 0.483 0.04 0.875
Caspase 9 mRNA 0.258 0.334 -0.061 0.809
Caspase 10 mRNA 0.168 0.534 0.021 0.935
APAF-1 mRNA 0.515 < 0.01 0.107 0.153
TNFα mRNA -0.117 0.56 0.05 0.773
Perforin mRNA -0.117 0.56 0.028 0.872
KIR2DL2/3 mRNA -0.55 0.003 -0.17 0.328
NKG2D mRNA -0.156 0.437 -0.035 0.84
PD-1 mRNA 0.599 < 0.01 0.018 0.917
CTLA4 mRNA 0.03 0.89 0.183 0.37
TIM3 mRNA -0.034 0.878 0.153 0.445
IFNγ mRNA -0.135 0.439 0.033 0.833
CD8β mRNA -0.218 0.202 0.04 0.791
CD86 mRNA -0.121 0.481 0.188 0.216
biomarkers in serum
CK-18 0.201 0.098 0.762 < 0.01
Caspase 3/7 activity 0.26 0.071 0.774 < 0.01
soluble PD1 0.038 0.82 0.645 < 0.01
CXCL10 0.71 0.001 0.23 0.329
CXCL11 0.399 0.101 0.271 0.248
CCL5 0.324 0.189 0.153 0.518
CCL4 0.011 0.965 -0.047 0.845
CXCL9 0.002 0.995 0.209 0.377
All statistical tests were two-tailed and were considered significant at p 0.05.
doi:10.1371/journal.pone.0165533.t001
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CH6413 and CH1541 became elevated by days 47 and 61, respectively, peaking rapidly thereaf-
ter (Fig 3A). For CH256, the rise in sPD-1 levels was less marked. In CH6413 and CH256, lev-
els of sPD-1 decreased after its peak, but sPD-1 levels were elevated until day 138 in CH1541.
The level of sPD-1 in plasma correlated significantly with intrahepatic PD-1 mRNA (r = 0.491,
p = 0.001) and serumALT activity (r = 0.302, p = 0.035). Because of the lack of availability of
serum samples from CH1541, levels of CXCL10 in serumwere only determined in CH6413
and CH256. Baseline levels of CXCL10 were analyzed using 9 different pre-inoculation samples
and determined to be 112 pg/ml in CH6413 and 32 pg/ml in CH256. High levels of circulating
CXCL10 were detected from day 12 with 4.4-fold increase over baseline expression level in
CH6413 and a 6.5-fold increase in CH256, and these levels peaked at day 61 in CH6413 and 82
in CH256 (Fig 3B).
Fig 2. Expression of chemokines, NK cell and T cell co-activation and inhibition markers in liver. (A), Expression levels of chemokine mRNAs in
the liver during acute HCV infection: CCR7 (purple line), CCR1 (green line), CXCR3 (red line), and CXCL10 (blue line). (B), Expression levels of NK cell
marker mRNAs in the liver: KIR2DL2/3 (blue line) and NKG2D (red line). (C), T cell activation marker RNAs: CD8β (blue line), IFN-γ (red line), and CD86
(green line). (D), T cell inhibition marker mRNA expression in liver: PD-1 (red line), PD-L1 (blue line), Tim-3 (purple line), and CTLA4 (green line). Each
gene’s mRNA level was normalized to an endogenous reference gene and expressed as an increase over baseline liver tissue levels.
doi:10.1371/journal.pone.0165533.g002
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Correlation between hepatic mRNAs, HCV RNA concentration, and ALT
activity levels
The Pearson correlation test was performed to determine the relationship between levels of
hepatic mRNA expression, serum protein, and clinical parameters such as ALT activity and
presence of HCV RNA during acute HCV infection. A weak correlation was detected between
HCV RNA concentration and ALT activity. SerumHCV RNA levels were positively correlated
with the expression of 2OAS-1, PD-1, APAF-1, RIG-I, PD-L1 and CXCL10 mRNAs and
inversely correlated with CCR1 and KIR2DL2/3 mRNA expression (Table 1). Strong positive
correlations were detected betweenALT activity and CK-18, Caspase 3/7 activity, and soluble
PD-1. These results indicate that hepatic expression of 2OAS-1, PD-1, APAF-1, RIG-I, PD-L1
and CXCL10 mRNAs was activated during HCV RNA replication. Statistically significant cor-
relations were not detected between any of hepatic mRNAs and ALT activity.
Lag correlation
A simple linear correlation test such as the Pearson correlation only allows determination of
linear relationships between two variables. Smooth trajectories as illustrated in Fig 4 provide a
picture of trends in expression levels of different mRNAs and ALT during acute phase HCV
infection. Trajectory curveswere generated based on levels of hepatic mRNA expression that
were up-regulated before the peak of ALT activity, at the peak, and after ALT activity peak in
each chimpanzee (Fig 4). High levels of hepatic expression ( 2-fold change) of 2OAS-1,
RIG-I, CXCL10, TLR3, and TLR7 mRNAs were detected before the ALT activity peak. Serum
levels of CK-18, Caspase 3/7 activity, and soluble PD-1 were elevated at the peak of ALT activ-
ity, and hepatic expression of PD-1, IFNγ, NKG2D, perforin, CXCL3, TNFα, and CCR7
mRNAs was up-regulated after peak of ALT activity. Based on these trends, lag correlation test-
ing was performed to determine the temporal relationship between these mRNAs and ALT
Fig 3. Serum levels of sPD-1 and chemokines. (A) Levels of serum sPD-1 (red line) were compared to ALT activity (gray shading). (B), serum levels of
CXCL9 (red line), CXCL10 (blue line), and CXCL11 (green line) in CH6413 and CH256. Serum samples of CH1541 were not available so serum levels of
chemokines by ELISA analysis could not be determined.
doi:10.1371/journal.pone.0165533.g003
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activity (Table 2). ALT activity was positively correlated with RIG-I, TLR3, CXCL10, PD-L1,
2OAS-1, Caspase 7, and Caspase 10 mRNA expression from 3 to 12 days before the peak of
ALT activity, indicating that the increase of these mRNA levels is associated with the subse-
quent increase in ALT activity. ALT activity was positively correlated with expression of mark-
ers for T cells and NK cells such as IFNγ, CD8β, CD86, KIR2D, and NKG2D mRNAs from 7 to
32 days after the peak of ALT activity, indicating that the expression of these genes was up-reg-
ulated after elevation of ALT activity.
Discussion
Experimentally infected chimpanzees allowed us to analyze the kinetics of host response
induced by acute HCV infection. Profiles of innate and adaptive immunologic responses and
those relating to cell death signaling biomarkers expressed in liver and serum provided insights
into early immune responses associated with liver injury during acute HCV infection.We
found that apoptosis markers, caspase 3/7 activity and CK-18, were positively correlated with
ALT activity and elevation of hepatic caspase 3 and 7 mRNA expression was detected earlier
than serum caspase 3/7 activity and M30 antigen. These results demonstrated evidence for
association between apoptosis and liver damage during acute HCV infection. Two apoptotic
pathways, intrinsic and extrinsic, are converging on activation of effector caspases but require
different initiation caspases to start the process. The intrinsic apoptosis pathway occurs
Fig 4. Smoothed trajectories of each hepatic mRNA expression compared to ALT activity during acute HCV infection. Hepatic expression of
mRNAs was up-regulated before the peak (A), at the peak (B), and after the peak of ALT activity.
doi:10.1371/journal.pone.0165533.g004
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through cytochrome c released after mitochondrial damage, activation of initiator caspases,
caspase 9 and APAF-1, and subsequent effector caspase 3 and caspase 7 activation [32]. For
extrinsic apoptosis, TNFα, a pleiotropic pro-inflammatory cytokine produced mainly by acti-
vated macrophages, can initiate apoptosis through death receptors in hepatocytes leading to
subsequent liver injury [33]. We found that caspase 9 and adaptor molecule, APAF-1 mRNA
expression was detected in all three chimpanzees and APAF-1 mRNA expression was elevated
as early as 12 days after inoculation (Fig 1D) and elevation of TNFαmRNA expression was
detected either after the peak of ALT activity (days 82 or 95 in CH6413 and CH256) or not
detected (CH1541). These results suggest that apoptosis could occur through the mitochon-
drial-mediated, intrinsic pathway rather than the extrinsic pathway during the acute phase of
HCV infection. A previous study reported that HCV infection induced mitochondrial-medi-
ated apoptosis pathway in which the increased accumulation of the proapoptotic protein Bax,
resulted in release of cytochrome c after mitochondrial swelling and activation of caspase 3 in
HCV-infected Huh 7.5 cells [34].
Innate immune responses provide the first line of defense against HCV infection. Type I
IFN, IFNα/β, and type III IFN, IFN-λ, responses induced similar sets of interferon-stimulated
genes (ISG) [35]. Up-regulation of type III IFN, IL-28 and IL-29 mRNA were detected in liver
and increased levels of IL-28 and IL-29 protein in serumof chimpanzees with acute HCV infec-
tion [20, 21]. RIG-I, TLR3, and TLR7, and induce interferons, cytokines, and chemokines dur-
ing HCV infection [36, 37]. RIG-I mediated IFN response was shown to play an important role
in controlling virus infection in HCV-infected cells [38]. In other reports, RIG-I signaling and
Table 2. Lag correlation coefficients between ALT activity and other markers based on the Pearson
correlation model.
mRNA markers Lag time in days r p
RIG-1 mRNA 14 0.1597 0.0391
TLR3 mRNA 0 -0.1959 0.0082
TLR7 mRNA 0 -0.2126 0.0041
CXCL10 mRNA 10 0.533 < 0.001
PD-L1 mRNA 10 0.5324 < 0.001
2OAS-1 mRNA 31 0.7713 < 0.001
CASP3 mRNA -53 0.4865 < 0.001
CASP7 mRNA 24 0.2634 0.0009
CASP8 mRNA -17 0.6791 < 0.001
CASP9 mRNA -17 0.4554 < 0.001
CASP10 mRNA 10 0.9063 < 0.001
CXCL3 mRNA -53 0.6199 < 0.001
CCR1 mRNA -53 0.7496 < 0.001
CCR7 mRNA -17 0.4577 < 0.001
IFNγ mRNA -109 0.4555 0.0001
CD86 mRNA -24 0.634 < 0.001
CD8β mRNA -46 0.8775 < 0.001
PD-1 mRNA -24 0.713 < 0.001
CTLA4 mRNA -32 0.6516 < 0.001
Tim-3 mRNA -53 0.8159 < 0.001
KIR2DL2/3 mRNA -74 0.6412 < 0.001
NKG2D mRNA -81 0.8001 < 0.001
perforin mRNA -81 0.6256 < 0.001
TNFα mRNA -81 0.6856 < 0.001
doi:10.1371/journal.pone.0165533.t002
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TLR-3 signaling are required for CXCL10 induction in hepatocytes during early HCV infection
but type I or type III IFNs are not required in the initial induction phase [39]. These in vitro
infection studies were conducted in an independent system but inflammatory and antiviral
pathways operate simultaneously to control virus infection [40]. We also observed that up-reg-
ulation of hepatic expression of 2OAS-1, RIG-I, TLR3, TLR7, and CXCL10 mRNAs was found
as early as 7 days after infection and coincident with serumHCV RNA appearance (Figs 1 and
2). These results indicated that PRRs-mediated antiviral pathways, type I and type III IFNs
responses, and proinflammatory chemokines are produced by HCV-infected hepatocytes at
the same time and establish a strong antiviral state in chimpanzees during the acute hepatitis C
infection.
IFN-inducible gene, 2OAS-1, proinflammatory cytokines, and chemokines are involved in
eliminating viral infection from infected cells and induce apoptosis of infected cells. HCV-
mediated activation of RNase L, 2OAS-dependent ribonuclease, leads to apoptosis and elimina-
tion of HCV-infected cells. Apoptosis initiated by RNase L is characterized by the release of
cytochrome c from mitochondria and requires caspase 3 activity [41]. TLR3 can directly trigger
apoptosis in human cancer cells [42]. CXCL10 expression was correlated with liver cell apopto-
sis in humans and mice, and apoptosis occurs through noncognate receptor TLR4 [36]. Up-
regulation of CXCL10 expression was observed in patients who inject drugs and associated
with subsequent increase in ALT levels during acute hepatitis C infection [37]. In our study,
hepatic 2OAS-1 mRNA was positively correlated with caspase 3/7 activity (r = 0.504, p = 0.02),
hepatic RIG-I mRNA expression was positively correlated with caspase 3 mRNA expression
(r = 0.669, p = 0.034), and CXCL10 mRNA expression was positively correlated with caspase 7
mRNA expression (r = 0.711, p = 0.014). We also observed elevation of ALT activity after
increases in each of these mRNA levels. Expression profiles of these genes indicated that early
expression of 2OAS-1, RIG-I, TLR3, and CXCL10 was associated with increases in HCV RNA
levels, and followed elevation of ALT activity at 10 to 12 days before the peak of ALT activity
(Table 2). These results suggest that 2OAS-1, RIG-I, TLR3, and CXCL10 are involved in induc-
ing apoptosis upon HCV infection and lead to liver injury in acute HCV infection.
NK cells and CD8+ T cells were shown to be involved in elimination of HCV infected hepa-
tocytes [43, 44]. In our study, expression of NKG2D and KIR2D mRNAs, hepatic NK cell
markers, markers for T cell activation (CD86, CD8β, and IFNγ) and T cell inhibition markers
(PD-1, CTLA4) were up-regulated after the peak of ALT activity in all three chimpanzees (Fig
2). Lag correlation analysis showed NK cell markers, T cell activation/inhibitionmarkers were
negatively correlated with ALT activity. T cell and NK cell-induced hepatocyte apoptosis was
mediated largely by members of the TNF receptor family including TNFα, Fas, and TRAIL
[45]. We found that elevation of TNFαmRNA expression was detected either after the peak of
ALT activity or not elevated, suggesting that elimination of HCV infected hepatocytes by T
cells and NK cells may not lead to elevation of ALT activity in experimentally infected chim-
panzees with acute HCV infection.
Increase in serum levels of caspase 3/7 activity, CK-18, and soluble PD-1 have strong posi-
tive correlation with ALT activity during acute HCV infection (Fig 4). Currently serumALT
activity is used as marker for liver injury but it cannot distinguish between acute and chronic
HCV infection. Acute hepatitis C is defined by the presence of any sign or symptom of acute
viral hepatitis plus either jaundice or elevated ALT activity, with presence of anti-HCV anti-
body or HCV RNA [3]. However, most people with acute HCV infection are asymptomatic at
time of diagnostic testing and already positive for anti-HCV antibody. The chimpanzee model
of HCV infection allows host responses to be analyzed closely, particularly during the early
stage of infection. Previously we reported that serum levels of miR-122 were positively corre-
lated with ALT activity during acute HCV infection [6]. SerumCK-18 levels showed high
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sensitivity and specificity in diagnosing non-alcoholic steatohepatitis in patients with non-
alcoholic fatty liver disease and reflected clinical diseasemore accurately than ALT levels
[46, 47]. A meta-analysis of elevated serum cytokeratin-18 levels in hepatitis showed its
clinical value for identifying the development of hepatitis [48]. The biomarkers such as CK-18,
caspase 3/7 activity, sPD-1, and serum miR-122 levels could be used as adjunctive criteria to
diagnose acute hepatitis C more definitively and to provide a sharper case definition for acute
hepatitis C.
In summary, we found that cell death signaling is initiated by early induction of RIG-I,
TLR3, and CXCL10 mRNAs and type I IFN response causing elevation of ALT activity, and
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